Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Brief summary (registry, in English)

The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 1182
• From 11 Jan 2024 to the primary completion date, 6 Dec 2027
• 186 sites in 27 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (186)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Related publications

• Patient engagement in protocol development for rare disease clinical trials: a framework.Res Involv Engagem · 2026 · PMID 42855714